DailyIQ
DailyIQ
Last updated1 minute ago

NTRA·Natera, Inc.

$272.94
-16.72 (-5.77%)
After Hours
High
$290.06
Open
$286.69
Market Cap
39.64B
52W High
$444.72
Low
$271.85
P. Close
$272.94
P/E
-
52W Low
$181.00
Fwd P/E
-788.67
DailyIQ Est.
$437.89
Inst. Own.
75.6%
Short Interest
4.20%
Days to Cover
4.2
NewEarnings release, scored · filed Nov 5, 2026tone -10.2 vs prior release · 56 lines scoredSee the breakdown
Technical Score (1D)
96
BULLISH
News Sentiment
70
BULLISH
With a Technical Score of 96, Natera, Inc. (NTRA) sits in the upper tier of the momentum ranking on the 1D timeframe. The bullish bias and BUY signal follow from that rank, and trend strength reads as strong. Sentiment at 70 is aligned with the chart. Because the score is relative, it can stay high while the broader market falls, as long as NTRA holds up better than its peers. $276.47 is the near-term risk reference and $308.15 is the next upside marker if buyers keep pressing. DailyIQ's indicator breakdown shows how individual readings such as RSI (neutral range) and MACD (bearish) look right now. Those readings are context only and do not feed the Technical Score, which ranks NTRA's momentum against the rest of the universe.
LOW TARGET
$280 +2.4%
1 analysts
MEAN TARGET
$412 +50.8%
16 analysts
HIGH TARGET
$500 +82.9%
16 analysts
PRICE RANGE
$280.00 - $500.00
SB / B / H / S / SS
12/16/3/1/1
DAILYIQ EST.
$437.89 (+60.2%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NMS
Country
United States
Website
Symbol
NTRA
Description
Natera, Inc. is a global diagnostics company specializing in molecular testing services. The company's core value proposition lies in its comprehensive suite of tests, including non-invasive prenatal screenings like Panorama, and tests for hereditary cancer and organ transplant rejection. Natera also offers tests for single-gene disorders, preimplantation genetic screening, and miscarriage analysis, serving a broad range of clinical needs. Through its direct sales force and partnerships with laboratories and distributors, Natera provides its services to a diverse customer base including medical centers and research institutions. The company also collaborates with other entities to develop and commercialize advanced genetic testing solutions.
Bought (1Y)
0 shares
$0
Sold (1Y)
660,233 shares
$191.1M
Sheena Jonathan-
Sell80 shares2026-11-11
Sheena Jonathan-
Sell120 shares2026-11-11
Sheena Jonathan-
Sell182 shares2026-11-11
Sheena Jonathan-
Sell48 shares2026-11-11
Sheena Jonathan-
Sell160 shares2026-11-11
74/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✕Negative net margin
✓Positive operating cash flow
Gross Margin
4.3%
Net Margin
-9.0%
Revenue CAGR
36.5%
Current Ratio
3.39x
Debt / Equity
0.21x
Return on Equity
-12.2%
Earnings Summary
In Q4 2024, the company reported an EPS of –$0.41 versus an estimate of –$0.35, and revenue of $476.1 million, indicating a modest revenue increase but a slight EPS miss. The following quarter, Q2 2026, saw EPS improve to –$0.47 against an estimate of –$0.53, while revenue surged to $752.8 million from an estimate of $673.9 million, reflecting accelerated top‑line growth and a narrowing earnings gap. Q3 2026 continued this trend with EPS of –$0.42 versus –$0.30 expected, and revenue of $794.0 million against an estimate of $719.0 million, underscoring consistent revenue outperformance despite lingering negative earnings. Historically, Natera has shown a YoY revenue growth trajectory, with each quarter in 2026 exceeding analyst expectations for top‑line growth, while EPS has remained negative but improving, suggesting a pattern of revenue expansion coupled with gradual earnings stabilization. Recent news highlights the company’s recognition as Best‑in‑Class for its Signatera molecular residual disease test at the 2026 HLTH Conference, reinforcing its leadership in precision medicine. Additionally, the CFO’s announcement of a $6 billion 2029 revenue target, driven by Signatera expansion and colorectal cancer screening studies, signals a strategic focus on high‑margin growth initiatives.

EPS

EstBeatMiss
$-0.59$-0.47$-0.34$-0.21$-0.08Q4'24Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$-0.14 - -
Q3'26$-0.30$-0.42-40.7%
Q2'26$-0.53$-0.47+12.0%
Q4'24$-0.35$-0.41-18.3%

Revenue

EstBeatMiss
$428M$533M$638M$743M$848MQ4'24Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$800M - -
Q3'26$719M$794M+10.4%
Q2'26$674M$753M+11.7%
Q4'24 - $476M -

Market Data

NTRA Stock Snapshot

BULLISH96/100
$274.16+$1.22 (0.4%)
Market cap
39.64B
Day range
$271.85 – $290.06
News sentiment
70/100 · Bullish
Analyst target
$412.36 (+50.4%)
Consensus
Buy · 33 analysts
52-week range+51.5% off low · -38.4% from high
$181.00$444.72
Price $274.16 DailyIQ Est. $437.89

NTRA's technical picture is constructive, with trend and momentum pointing the same direction. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What NTRA's own history says about today's numbers

Realized volatility (21d)
101.1% 97th pct
Below its peak
-36.8%
vs 200-day average
+0.2%
Up days (1y)
51%

Natera, Inc. is currently running 101.1% annualised volatility over the last 21 sessions. Measured against NTRA's own 11 years of daily returns rather than a market-wide average, that is the 97th percentile — an extreme by its own standards, against a typical reading of 51.5%.

NTRA is trading -36.8% below its running peak. Across 11 full years on file, its median worst-drawdown-in-a-year was -37.2%, and the deepest was -70.3% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +0.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 28th percentile — a narrower gap than it typically runs. Over the past year NTRA closed higher on 51% of sessions, and it is currently 1 session into a falling streak.

On November specifically: over 12 years of records, NTRA finished the month higher 6 of 12 times, with a median return of +0.9% and an average of +6.9%. Its strongest month historically has been August at +14.8% on average, its weakest October at -3.7%.

Overnight risk is measurable too: NTRA has opened more than 2% away from the prior close in 306 of 2,864 sessions (10.7% of the time), with the largest gaps running +12.3% and -18.8%.

All figures computed from 2,865 daily closes between 2015-07-02 and 2026-11-20, split-adjusted, recomputed daily. Percentiles are against NTRA's own 11-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of NTRA's sector?

Natera, Inc. sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#5 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for NTRA?

CallsPuts

For Natera, Inc.'s nearest expiry (2026-12-18, 26 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 2.56), with at-the-money implied volatility around 63.3%. The options market is pricing roughly a ±16.8% move by that expiry — a range of about $249.23–$349.65.

Put/call ratio (2026-12-18)
2.56
ATM implied volatility
63.3%
Total open interest
2,316
Expected move by 2026-12-18
±16.8% ($249.23–$349.65)

Analyst Rating Changes

Are analysts turning bullish or bearish on NTRA?

Baird most recently reiterated its rating on Natera, Inc. to Outperform on Nov 9, 2026 with a price target of $403 (from $458). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Baird: Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Nov 9, 2026BairdMaintainedOutperform$458 → $403
Nov 6, 2026JP MorganMaintainedOverweight$460 → $405
Nov 6, 2026Evercore ISI GroupMaintainedOutperform$468 → $400
Oct 27, 2026BTIGMaintainedBuy$320 → $430
Oct 19, 2026Canaccord GenuityMaintainedBuy$375 → $500
Oct 14, 2026JP MorganMaintainedOverweight$360 → $460
Oct 13, 2026Morgan StanleyMaintainedOverweight$355 → $435
Oct 13, 2026TD CowenMaintainedBuy$340 → $480
Oct 7, 2026BarclaysMaintainedOverweight$340 → $475
Oct 6, 2026CitigroupMaintainedBuy$365 → $480
Oct 1, 2026GuggenheimMaintainedBuy$360 → $475
Sep 25, 2026RBC CapitalMaintainedOutperform$350 → $460

Earnings Release, Scored

What did Natera, Inc.'s latest earnings release say?

Filed Nov 5, 2026 · SEC Form 8-K, Exhibit 99

Tone66.7/ 100-10.2 vs prior release
Hedging words3.32per 100 words+0.61 vs prior release
Tone, last 3 releasesScale 50–82

Most important lines

  1. 1

    Increased cash by approximately $5.7 million 3 as of September 30, 2026 compared to June 30, 2026.

    New this quarter
  2. 2

    Changes in estimates for the three months ended September 30, 2026 and 2025 increased revenue and, as a result, increased gross margin 1 by 1.5% and 3.6%, respectively, and increased gross profit 1 by $32.3 million and $55.1 million, respectively.

  3. 3

    Excluding revenue true-ups, third quarter non-GAAP gross margin 2 increased by 137 basis points over the second quarter of 2026.

Peers & ETF holders

NTRA peers & ETF holders

News & sentiment

What is the news saying about NTRA?

NTRA fell 33.1% over the month to Nov 20. News tone held between 42 and 77 from Oct 20 to Nov 17, then dropped to 0 on Nov 19.

Daily close and news tone, Oct 20 to Nov 20
$300$400Oct 20: tone 75Oct 21: tone 50Oct 22: tone 54Oct 23: tone 70Oct 26: tone 45Oct 27: tone 66Oct 28: tone 75Oct 29: tone 42Oct 30: tone 53Nov 2: tone 44Nov 3: tone 64Nov 4: tone 68Nov 5: tone 53Nov 6: tone 60Nov 9: tone 77Nov 10: tone 72Nov 11: tone 52Nov 12: tone 75Nov 13: tone 53Nov 16: tone 42Nov 17: tone 74Nov 18Nov 19: tone 0Nov 20: tone 50Oct 20News toneNov 20123
  1. Nov 2 -8.9%same day: Natera Insider Sold Shares Worth $1,313,470, According to a Recent SEC Filing
  2. Nov 5 -22.4%same day: Natera Reports Third Quarter 2026 Financial Results
  3. Nov 16 -7.9%

Technical analysis

How strong is NTRA's momentum right now?

On the daily chart NTRA ranks at the 96th percentile for momentum against 1,063 stocks and ETFs, a bullish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling NTRA?

99 of the 202 tracked managers added to NTRA in their latest 13F and 99 trimmed. Together they own 75.6% of the company, worth $45.1B. JPMorgan Chase and Fidelity alone hold 19.2%.

99adding99trimming4unchanged
Largest holders by stake, latest 13FBar = share of NTRA
  1. $5.8B positionAdded 9.1% last quarter
  2. $5.7B positionAdded 151.0% last quarter
  3. $4.4B positionTrimmed 2.8% last quarter
  4. $2.6B positionAdded 0.2% last quarter
  5. $2.4B positionTrimmed 0.8% last quarter
  6. $1.5B positionAdded 0.8% last quarter
  7. $1.2B positionTrimmed 29.6% last quarter
  8. $1.1B positionTrimmed 2.0% last quarter
  9. $1.0B positionTrimmed 4.5% last quarter
  10. $1.1B positionAdded 17.2% last quarter
Full holdings history

Congressional trading

Is Congress trading NTRA?

2 members of Congress disclosed 4 NTRA trades between Apr 20, 2021 and Sep 22, 2025: 2 buys and 2 sells, about $32.0K in estimated value.

BuysSells2022202320242025
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart

Discover more

How has NTRA done against its peers?

Over the six months to Nov 20, NTRA returned +33.4%. Of the 15 related stocks and ETFs, 9 did better, led by CRL at +101.4%.

Change since May 20, through Nov 20
−50%0%+50%+100%+150%May 20JulAugSepOctNovNov 20CRL +101.4%NTRA +33.4%XLV +20.5%